BIOA

Lecanemab Efficacy and Safety: Recent findings presented at the Alzheimer's Association International Conference indicate that lecanemab (Leqembi®) significantly slows cognitive decline in early Alzheimer's patients, with a consistent safety profile over four years of treatment. The data shows that 95% of participants from the core study opted to continue treatment, demonstrating sustained benefits.

Subcutaneous Dosing Development: Eisai is exploring subcutaneous dosing options for lecanemab, which may enhance patient convenience and adherence. Initial studies suggest that this method maintains efficacy comparable to intravenous administration while reducing the incidence of adverse reactions, potentially transforming treatment delivery for early Alzheimer's disease.

Leqembi Sales Performance: BioArctic's partner Eisai reported that Leqembi generated global sales of JPY 23.1 billion in Q2 2025, resulting in a royalty of SEK 162.5 million for BioArctic, marking a 280% increase from the previous year.

Ongoing Clinical Studies and Collaborations: Lecanemab, developed through a partnership between BioArctic and Eisai, is approved in 46 countries for early Alzheimer's treatment and is involved in multiple ongoing clinical studies aimed at further understanding its efficacy in various stages of Alzheimer's disease.

BioArctic and Eisai's Achievement: BioArctic AB's partner, Eisai, announced that their co-developed Alzheimer's drug lecanemab (Leqembi®) has received the 9th Bioindustry Award from the Japan Bioindustry Association for its innovative research in treating early Alzheimer's disease.

Company Background and Future Plans: Founded by Professor Lars Lannfelt, BioArctic focuses on neurodegenerative diseases and is preparing for joint commercialization of Leqembi in the Nordic region alongside Eisai, which leads global development and regulatory submissions.